DIGESTIVE REDS
DEAD

Serial Number

97784098

Owner

BIOHM HEALTH INC.

Attorney

Brian E. Turung

Filing Date

Feb 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DIGESTIVE REDS Trademark

Serial Number: 97784098

DIGESTIVE REDS is a trademark filed by BIOHM HEALTH INC. on February 7, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BIOHM HEALTH INC. (51 trademarks)

425 LITERARY ROAD
CLEVELAND, OH 44113

Entity Type: 99

Trademark Details

Filing Date

February 7, 2023

Registration Date

Not Registered

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; dietary supplements for medical use, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; fungal extracts sold as a component ingredient of nutritional supplements and vitamins and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's disease, ulcerative colitis and irritable bowel syndrome

Filing History

ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE
Aug 18, 2024 MAB0
ABANDONMENT - INCOMPLETE RESPONSE
Aug 5, 2024 ABN0
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 5, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 5, 2024 GNFN
FINAL REFUSAL E-MAILED
May 5, 2024 GNFR
FINAL REFUSAL WRITTEN
May 5, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 26, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 26, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 25, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 4, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 26, 2023 NWOS